Subject 2: Scan 2(c) (10/9/2004)

Fig. 2-c. Third bone density scan (Achilles Ultrasonometer) of subject 2 (female, age 57 years) nine months after second scan, and 11 months after last taking OsteoPhase during evaluation phase. Results indicated a continued increase in BMD between 2nd and 3rd scan, from 75% to 77% (yellow highlighted area), indicating continuing and sustained benefits from the formula.

All contents Copyright © 2008 Tango Advanced Nutrition, Inc. All rights reserved. AllerPhase®, ArthriPhase™, BronchoPhase®, CardioPhase®, Daily Movement™, FemmePhase®, Herbal Boost™, ImmunoPhase®, MetaPhase®, OsteoPhase®, PriaPlex®, Pure Tango®, SleepCycle™, Tango® and Vital Cell® are registered trademarks of Tango Advanced Nutrition, Inc. The content provided by this site is for informational purposes only and has not been approved by the U.S. FDA. This site is not intended to provide personal medical advice, which should be obtained from a medical professional.